AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35929037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dexmedetomidine (Dex) and Butorphanol (But)
Trial: 33041028
Drug: Nucleotide supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide supplementation (2 g/d)
Trial: 616503306
Drug: Therapy-related factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy-related factors (patient-rated pretreatment credibility and early therapeutic alliance)
Trial: 35366822
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound treatment for 8 weeks
Trial: 33753537
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K Antagonists (VKAs) with target INR of 2-3
Trial: 33203477
Drug: Biannual community-wide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual community-wide treatment (CWT)
Trial: 33203477
Drug: Annual school-based
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual school-based treatment (SBT)
Trial: 33279558
Drug: Phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate binder prescriptions and dietary recommendations to achieve 'Hi' serum phosphate target (≥6.5 mg/dl)
Trial: 33279558
Drug: Phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate binder prescriptions and dietary recommendations to achieve 'Lo' serum phosphate target (<5.5 mg/dl)
Trial: 32753845
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 mg (test formulation)
Trial: 32753845
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 mg (reference formulation)
Trial: 32753845
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of glimepiride
Trial: 32202698
Drug: Randomized spacer
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized spacer region in the translation initiation site; specific details on dosage and duration not available.
Trial: 36088952
Drug: Oral amoxicillin-clavulanic
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin-clavulanic acid (75 mg/kg amoxicillin + 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Trial: 36088952
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (according to local protocol, for 7 days)
Trial: 36088952
Drug: Oral amoxicillin-clavulanic
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin-clavulanic acid
Trial: 32584174
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (10 mg/site)
Trial: 32584174
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl (10 mg/site)
Trial: 35688444
Drug: Hyperosmolar saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar saline (593 mOsm/L)
Trial: 35688444
Drug: Isotonic lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic lactated Ringer's (273 mOsm/L)
Trial: 36130170
Drug: Referral resources
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral resources on evidence-based cessation treatments (control)
Trial: 33185670
Drug: Evolocumab, 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab, 140 mg every 2 weeks or 420 mg monthly
Trial: 33185670
Drug: Simvastatin, 40
RxNorm normalized name: Simvastatin, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 40 mg daily for 30 days followed by 80 mg daily thereafter
Trial: 33185670
Drug: Ezetimibe, 10
RxNorm normalized name: Ezetimibe, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe, 10 mg daily plus simvastatin, 40 mg daily
Trial: 34110701
Drug: Glucose ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingestion (CHO) - 300 ml water containing 75 g glucose
Trial: 33715526
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g.kg‐1 BM)
Trial: 33715526
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (0.3 g.kg‐1 BM)
Trial: 32713104
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (STT)
Trial: 32841751
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using methylene blue followed by IPL illumination
Trial: 32841751
Drug: Candida antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida antigen immunotherapy using 0.1 ml of candida albicans antigen
Trial: 32841751
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 0.1 ml saline
Trial: 32845808
Drug: Bioabsorbable steroid-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-eluting sinus stents
Trial: 33568346
Drug: dose-dense methotrexate-vinblastine-adriamycin-cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC), given every 14 days for four cycles
Trial: 34957976
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose PTX (400 mg TID)
Trial: 34957976
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose PTX (200 mg TID)
Trial: 35636061
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based therapy (VRBT) once a week
Trial: 33378403
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Trial: 33378403
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 14 days, adding metronidazole 500 mg and clarithromycin 500 mg twice daily in the last 7 days)
Trial: 36064491
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch
Trial: 32157524
Drug: Chemo/targeted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo/targeted therapy
Trial: 35447085
Drug: SCB-2019 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 (two doses, 21 days apart)
Trial: 35447085
Drug: SCB-2019 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 (one dose)
Trial: 34024504
Drug: Dietary counselling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counselling and daily oral nutritional supplement (ONS) containing 33.8 g of protein, 2.2 g EPA, and 1.1 g DHA
Trial: 32585223
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (4 intracervical injections of bupivacaine hydrochloride 0.5%)
Trial: 33180175
Drug: Blonanserin (12.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (12.8 ± 5.6 mg/day)
Trial: 33180175
Drug: Olanzapine (10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10.8 ± 6.0 mg/day)
Trial: 33180175
Drug: Blonanserin (D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (D3 receptor)
Trial: 33180175
Drug: Olanzapine (D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (D2 receptor)
Trial: 35783867
Drug: Xinnaoning Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinnaoning Capsule (XNNC)
Trial: 32764878
Drug: Ondansetron administered
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron administered 5 min before intrathecal injection
Trial: 32764878
Drug: Ondansetron administered
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron administered 15 min before intrathecal injection
Trial: 32764878
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 5 min or 15 min before intrathecal injection
Trial: 32219502
Drug: Scheduled combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled combination therapy with carboplatin/paclitaxel plus oregovomab
Trial: 35763763
Drug: eGFR values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR values lower than 50 ml/min/1.73 m2
Trial: 35445718
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with Lucitanib
Trial: 35445718
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with Lucitanib
Trial: 34511515
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (CI) including non-nutritive sucking (NNS), oral motor stimulation, and oral support
Trial: 35811140
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection analgesia
Trial: 32168298
Drug: IV tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tirofiban infusion
Trial: 33848675
Drug: Hydroxychloroquine (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (not specified dosage or duration)
Trial: 32053634
Drug: CC-only resuscitation
RxNorm normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-only resuscitation
Trial: 36308135
Drug: Basal salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal salt solution plus technique (Group 2 - BSS)
Trial: 33947367
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (patient education and physiotherapy)
Trial: 32227554
Drug: GSK2798745 (TRPV4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2798745 (TRPV4 antagonist)
Trial: 33059997
Drug: Iodine-125 (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-125 (125I) brachytherapy, prescription dose 144 Gy
Trial: 33059997
Drug: Cesium-131 (131Cs)
RxNorm normalized name: Cesium
DrugBank: Cesium (DB15392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cesium-131 (131Cs) brachytherapy, prescription dose 115 Gy
Trial: 32585017
Drug: Sildenafil, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil, 25 mg, 3 times a day
Trial: 34261807
Drug: Genicular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genicular nerve blockade (15 mL 0.25% bupivacaine and 2 mg dexamethasone)
Trial: 33834250
Drug: Interviewer knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer knowledge treatment (trained interviewers)
Trial: 34017029
Drug: Pulse D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse D therapy (60,000 IUs of vitamin D daily for 8 or 10 days depending on BMI)
Trial: 34017029
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (NVD group)
Trial: 33208170
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) boost after urgent 3D conformal radiotherapy (3DCRT)
Trial: 35379238
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg up to three times daily
Trial: 33071273
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise plus leucine supplement (RL)
Trial: 34133981
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (amoxicillin 500mg) under fasted conditions
Trial: 34133981
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (amoxicillin 500mg) under fed conditions
Trial: 34133981
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (amoxicillin 500mg) under fasted conditions
Trial: 34133981
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (amoxicillin 500mg) under fed conditions
Trial: 32306991
Drug: Ginger tablets
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger tablets (126 tablets for six weeks)
Trial: 32306991
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (126 tablets for six weeks)
Trial: 35130946
Drug: whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: whole cell pertussis (wP) vaccine
Trial: 35130946
Drug: acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acellular pertussis (aP) vaccine
Trial: 32290521
Drug: Leucine-Enriched Essential
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-Enriched Essential Amino Acids (LEAAs) 4 g thrice daily for four days
Trial: 32533536
Drug: ASP4345 (3–150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4345 (3–150 mg multiple oral doses)
Trial: 32533536
Drug: ASP4345 (3–900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4345 (3–900 mg single oral doses)
Trial: 32533536
Drug: ASP4345 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4345 (300 mg single oral dose)
Trial: 33199274
Drug: Fasinumab 9
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab 9 mg subcutaneous every 4 weeks (Q4W)
Trial: 33199274
Drug: Fasinumab 9
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab 9 mg intravenous every 8 weeks (Q8W)
Trial: 33199274
Drug: Fasinumab 6
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab 6 mg
Trial: 33199274
Drug: Fasinumab 9
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab 9 mg intravenous
Trial: 34802955
Drug: Classical music
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical music listening (ML)
Trial: 34351590
Drug: Oliceridine (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oliceridine (0.1, 0.35, or 0.5 mg)
Trial: 34351590
Drug: Pooled data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled data of Morphine
Trial: 33356640
Drug: Multimodal exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal exercises integrated with cognitive-behavioural therapy
Trial: 34407037
Drug: Heparinized solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized solution 100 U/mL (10 mL)
Trial: 34407037
Drug: Heparinized solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized solution 10 U/mL (20 mL)
Trial: 34407037
Drug: Heparinized solution
RxNorm normalized name: heparin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized solution 10 U/mL (30 mL)
Trial: 34407037
Drug: Urokinase solution
RxNorm normalized name: urokinase Injectable Solution
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urokinase solution
Trial: 34407037
Drug: Heparin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin at 10 U/mL
Trial: 34964149
Drug: Galantamine 16
RxNorm normalized name: galantamine 16 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 16 mg
Trial: 32473887
Drug: Drug-Coated Balloons
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloons (DCBs)
Trial: 35468321
Drug: Tirzepatide (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (pooled 10 mg and 15 mg)
Trial: 36045192
Drug: Checklist-guided medication
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checklist-guided medication review and communication stimulus
Trial: 39460685
Drug: Lacosamide (LCM)
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide (LCM) as adjunctive therapy
Trial: 35225634
Drug: Twice-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sessions of psychotherapy
Trial: 35225634
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of psychotherapy
Trial: 34493496
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (usual care plus measuring skin temperatures at 6-8 plantar sites per foot each day)
Trial: 34493496
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (with hotspot monitoring and activity reduction)
Trial: 34493496
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (podiatric treatment, education, and therapeutic footwear)
Trial: 34493496
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy
Trial: 32919816
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (100,000 IU monthly) in participants with 25(OH)D < 50 nmol/L
Trial: 32919816
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in participants with 25(OH)D < 50 nmol/L
Trial: 34180035
Drug: Fostemsavir (HIV-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (HIV-1 attachment inhibitor)
Trial: 34547260
Drug: Intravenous platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous platelet inhibitors
Trial: 34289935
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 2,000 IU daily
Trial: 32880504
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based therapy (VRBT)
Trial: 32880504
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based therapy (VRBT) after 12 weeks
Trial: 34579954
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review with follow-up
Trial: 32456525
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) + Nutraceutical Compound (NC) containing Monacolin-K, Berberine Hydrochloride, t-Resveratrol, Quercetin, and Chromium (3 months)
Trial: 32456525
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) in monotherapy (3 months)
Trial: 32456525
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) + Nutraceutical Compound (NC)
Trial: 32456525
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) in monotherapy
Trial: 32950246
Drug: NOL-guided fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NOL-guided fentanyl dosing
Trial: 32950246
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (fentanyl dosing based on haemodynamics)
Trial: 34526307
Drug: H3 diet
RxNorm normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H3 diet (n=61) - increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy
Trial: 34526307
Drug: H3-L6 diet
RxNorm normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H3-L6 diet (n=61) - increase n‐3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy